NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/22/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3.35 mln
Float1.63 mln
Earnings Date08/14/2026
EPS
572
Exceptional
P / E
0.00
Anomalous
Piotroski F-Score
5
/ 9
Neutral
Relative Strength
67
/ 100
Outperforming
Debt / Equity
0.05
Debt-free
ROE
-134
Deeply negative
Business Description
Propanc Biopharma is an Australian biotech company focused on developing new treatments for pancreatic, ovarian, and colorectal cancers. Its main drug candidate, PRP, is an intravenous therapy that uses proenzymes to target and prevent cancer, and has already completed pre-clinical testing. The company works alongside the Universities of Jaén and Granada to advance its research programs and develop an improved synthetic form of PRP. Founded in 2007 and headquartered in Camberwell, Australia, Propanc Biopharma continues to build on its pipeline of cancer therapies.
